Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine

Sun, Xun; Provoda, Chester J.; Lee, Kyung Dall

doi:10.1016/j.jconrel.2010.06.017

Cited by 16 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An anionic liposome-polycation-DNA complex combined with LLO was used as vaccine by Sun and colleagues to deliver OVA-cDNA. This formulation produced an enhanced CD8 + T-cell response, higher CTL frequency and IFNγ production after stimulation by an OVA-specific peptide [Sun et al 2010]. Andrews and colleagues analyzed whether encapsulating CpGs in LLO liposomes would enhance cell-mediated immune response and skew T H 1-type responses in a protein antigenbased vaccine utilizing LLO liposomes.…”

Section: Listeriolysinmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

432

309

View full text Add to dashboard Cite

Liposomes and liposome-derived nanovesicles such as archaeosomes and virosomes have become important carrier systems in vaccine development and the interest for liposome-based vaccines has markedly increased. A key advantage of liposomes, archaeosomes and virosomes in general, and liposome-based vaccine delivery systems in particular, is their versatility and plasticity. Liposome composition and preparation can be chosen to achieve desired features such as selection of lipid, charge, size, size distribution, entrapment and location of antigens or adjuvants. Depending on the chemical properties, water-soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped within the aqueous inner space of liposomes, whereas lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adjuvants can be attached to the liposome surface either by adsorption or stable chemical linking. Coformulations containing different types of antigens or adjuvants can be combined with the parameters mentioned to tailor liposomal vaccines for individual applications. Special emphasis is given in this review to cationic adjuvant liposome vaccine formulations. Examples of vaccines made with CAF01, an adjuvant composed of the synthetic immune-stimulating mycobacterial cordfactor glycolipid trehalose dibehenate as immunomodulator and the cationic membrane forming molecule dimethyl dioctadecylammonium are presented. Other vaccines such as cationic liposome-DNA complexes (CLDCs) and other adjuvants like muramyl dipeptide, monophosphoryl lipid A and listeriolysin O are mentioned as well. The field of liposomes and liposome-based vaccines is vast. Therefore, this review concentrates on recent and relevant studies emphasizing current reports dealing with the most studied antigens and adjuvants, and pertinent examples of vaccines. Studies on liposome-based veterinary vaccines and experimental therapeutic cancer vaccines are also summarized.

show abstract

Section: Listeriolysinmentioning

confidence: 99%

Liposomes as vaccine delivery systems: a review of the recent advances

Schwendener

2014

Therapeutic Advances in Vaccines

432

309

View full text Add to dashboard Cite

show abstract

“…Kyung-Dall Lee and coworkers were the first to report on the ability of this protein to enhance cytosolic delivery of engineered nanocarriers [120]. Since then, LLO has been used in a number of investigations to enhance the delivery of biological macromolecules, including lipid-encapsulated proteins [121, 122], as well as lipoplexes [123, 124] and polyplexes for gene delivery [125-127]. More recently, mutants of the LLO protein with enhanced pore-forming activity have been identified, allowing lower concentrations of LLO to be used in macromolecular delivery formulations, thereby enhancing endosomal escape while reducing cytotoxicity [128].…”

Section: Design Strategies To Achieve Endosomal Escapementioning

confidence: 99%

Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus

Munsell¹,

Ross²,

Sullivan

2016

CPD

View full text Add to dashboard Cite

New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many of these structures has been significantly limited due to the need for more efficient strategies to deliver macromolecular therapeutics to desirable intracellular sites of action. Engineered nanocarriers that encapsulate peptides, proteins, or nucleic acids are generally internalized into target cells via one of several endocytic pathways. These nanostructures, entrapped within endosomes, must navigate the intracellular milieu to orchestrate delivery to the intended destination, typically the cytoplasm or nucleus. For therapeutics active in the cytoplasm, endosomal escape continues to represent a limiting step to effective treatment, since a majority of nanocarriers trapped within endosomes are ultimately marked for enzymatic degradation in lysosomes. Therapeutics active in the nucleus have the added challenges of reaching and penetrating the nuclear envelope, and nuclear delivery remains a preeminent challenge preventing clinical translation of gene therapy applications. Herein, we review cutting-edge peptide- and polymer-based design strategies with the potential to enable significant improvements in biopharmaceutical efficacy through improved intracellular targeting. These strategies often mimic the activities of pathogens, which have developed innate and highly effective mechanisms to penetrate plasma membranes and enter the nucleus of host cells. Understanding these mechanisms has enabled advances in synthetic peptide and polymer design that may ultimately improve intracellular trafficking and bioavailability, leading to increased access to new classes of biotherapeutics.

show abstract

“…Recently, one study demonstrated that an LLO-containing LPDII-DNA delivery system works effectively for DNA delivery and leads to efficient DNA priming through the adoption of a DNA primeprotein boost vaccination protocol. 113 These researchers used OVA as a model antigen and found that the incorporation of LLO into the LPDII gene delivery system heightened gene expression in vitro and enhanced OVA-specific CD8 + CTL responses in vivo. 113 The results of the study may imply that the design of an LLOcontaining LPDII delivery system for DNA-based vaccines to stimulate protective immunity against diseases, such as cancer, has noteworthy value for future research.…”

Section: Llo-based Anti-tumor Vaccine Developmentmentioning

confidence: 99%

“…113 These researchers used OVA as a model antigen and found that the incorporation of LLO into the LPDII gene delivery system heightened gene expression in vitro and enhanced OVA-specific CD8 + CTL responses in vivo. 113 The results of the study may imply that the design of an LLOcontaining LPDII delivery system for DNA-based vaccines to stimulate protective immunity against diseases, such as cancer, has noteworthy value for future research. Bacteria and their components, such as lipoteichoic acid (LTA), lipopolysaccharide (LPS), and CpG motifs, are some of the most potent inducers of DC maturation and can be easily sensed by the innate immune system.…”

Section: Llo-based Anti-tumor Vaccine Developmentmentioning

confidence: 99%